Can a new drug combo make stem cell transplants safer for frail AML patients?

This trial is testing whether a new conditioning regimen, called VABu, can improve outcomes for adults with acute myeloid leukemia (AML) who are in first remission but are too frail for standard transplant prep. The regimen combines venetoclax, azacitidine (or decitabine), and busulfan, given before an allogeneic stem cell transplant. The study will follow 42 participants to see how many survive for two years after the transplant, and also track relapse, transplant-related complications, and infections. The goal is to find a safer, more effective way to prepare frail patients for a potentially curative transplant.